Aclaris Therapeutics (ACRS) Total Non-Current Liabilities (2016 - 2026)

Aclaris Therapeutics' Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $44.1 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 11.36% year-over-year to $44.1 million; the TTM figure through Mar 2026 stood at $44.1 million (down 11.36% YoY), while the FY2025 annual figure was $46.4 million, down 17.29% from the prior year.
• Total Non-Current Liabilities was $44.1 million for Q1 2026 at Aclaris Therapeutics, down from $46.4 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $56.1 million in Q4 2024 to a low of $18.4 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $35.5 million across 5 years, with a median of $34.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities tumbled 64.1% in 2022, then surged 115.7% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $23.9 million in 2022, then surged by 42.52% to $34.0 million in 2023, then surged by 64.79% to $56.1 million in 2024, then dropped by 17.29% to $46.4 million in 2025, then fell by 4.97% to $44.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $44.1 million (Q1 2026), $46.4 million (Q4 2025), and $53.7 million (Q3 2025), per Business Quant data.